Results 211 to 220 of about 146,499 (323)
A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines
, 2000 Lars H. Jensen, Karin C. Nitiss, Angela Rose, Jiaowang Dong, Junfang Zhou, Hu Tao, Neil Osheroff, Peter Buhl Jensen, Maxwell Sehested, John L. Nitiss +9 moreopenalex +1 more sourceSupplementary Figure from Genome-Protective Topoisomerase 2a-Dependent G<sub>2</sub> Arrest Requires p53 in hTERT-Positive Cancer Cells
, 2023 Nicola Lockwood, Silvia Martini, Ainara Lopez-Pardo, Katharina Deiss, Hendrika A. Segeren, Robert K. Semple, Ian Collins, Dimitra Repana, Mathias Cobbaut, Tanya Soliman, Francesca D. Ciccarelli, Peter J. Parker +11 moreopenalex +1 more sourceClinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients
International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.What's new?
Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan +7 morewiley +1 more sourceActivities of the Novel Bacterial Topoisomerase Inhibitor OSUAB-0284 against the Biothreat Pathogen <i>Bacillus anthracis</i> and Its Type II Topoisomerases. [PDF]
ACS Infect DisMann CA, Halasohoris SA, Gray AM, Chua J, Spencer JL, Curry BJ, Babyak AL, Klimko CP, Cote CK, West JS, Mitton-Fry MJ, Meinig JM, Osheroff N. +12 moreeuropepmc +1 more sourceSupplemental Figures 1 - 4 from Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer
, 2023 Ruud H. Wijdeven, Baoxu Pang, Sabina Y. van der Zanden, Xiaohang Qiao, Vincent A. Blomen, Marlous Hoogstraat, Esther H. Lips, Lennert Janssen, Lodewyk F.A. Wessels, Thijn R. Brummelkamp, Jacques Neefjes +10 moreopenalex +1 more sourceExposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)‐Negative Breast Cancer
The Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.Abstract
Dato‐DXd (datopotamab deruxtecan) is an anti‐TROP2 antibody‐drug conjugate developed for the treatment of unresectable or metastatic hormone receptor‐positive, human epidermal growth factor receptor 2‐negative breast cancer (HR+/HER2‐BC) who have received prior endocrine‐based therapy and chemotherapy for unresectable or metastatic disease ...Zoey Tang, KyoungSoo Lim, Yu Jiang, Neelima Denduluri, Nana Rokutanda, Yuzhuo Pan, Ying Hong, Song Ren, Pavan Vajjah, Diansong Zhou +9 morewiley +1 more sourceData from NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma
, 2023 Jenna H. Burton, Christina Mazcko, Amy K. LeBlanc, Joseph M. Covey, Jiuping Ji, Robert J. Kinders, Ralph E. Parchment, Chand Khanna, Melissa Paoloni, Sue Lana, Kristen Weishaar, Cheryl A. London, William C. Kisseberth, Erika Krick, David M. Vail, M. Childress, Jeffrey N. Bryan, Lisa G. Barber, E.J. Ehrhart, Michael L. Kent, Timothy M. Fan, Kelvin Kow, Nicole Northup, Heather Wilson‐Robles, Joseph E. Tomaszewski, Julianne L. Holleran, Miguel Muzzio, Julie L. Eiseman, Jan H. Beumer, James H. Doroshow, Yves Pommier +30 moreopenalex +1 more source
